ALTSTATION.IO

Centene Corporation (CNC) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$37.75

Change

-5.44%

Market Cap

$18.55B

Avg Volume

7.0M

Company Overview

Centene Corporation specializes in providing healthcare programs and services to under-insured and uninsured individuals and families across the United States. The company operates mainly through four segments: Medicaid, Medicare, Commercial, and Other. Their offerings include Medicaid expansion, Medicare supplements, and health insurance products for commercial organizations. They also manage various clinical services and pharmacies, addressing a broad spectrum of healthcare needs.

Centene is a dominant player in the Medicaid market, where it serves millions of members. It holds a competitive edge due to its extensive network of healthcare providers and its focus on delivering tailored services to vulnerable populations. Key competitors include Anthem and UnitedHealth Group, which present ongoing challenges. Market dynamics, such as increasing regulatory pressures and the potential for healthcare reforms, can threaten Centene’s stability but also push innovation and efficiency.

Currently, Centene is in a growth phase, driven by strategic acquisitions and expansions in underserved markets. The recent acquisition of Magellan Health has enhanced their behavioral health services, positioning the company for future growth. While challenges exist, including regulatory scrutiny and market competition, their ongoing investments in technology and operational improvements indicate a proactive strategy to maintain their leadership in the healthcare sector.

Key Financials

Market Cap

$18.55B

Revenue

$167.68B

EBITDA

$3.90B

Gross Margin

11.7%

Profit Margin

-3.2%

Revenue Growth

21.5%

Total Cash

$19.24B

Total Debt

$17.58B

Free Cash Flow

$4.42B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

N/A

Forward P/E

9.37

Beta

0.49

52-Week High

$66.03

52-Week Low

$25.08

EPS

$-10.67

50-Day Avg

$41.86

200-Day Avg

$40.84

Price/Book

0.89

Technical Analysis

Over the 52-week period, Centene Corporation (CNC) has displayed a clear downward trend, particularly marked by a significant decline that began around mid-2022, with the price peaking near $60 in July before plummeting. Key resistance is evident at the $38.46 level, which aligns closely with the recent price action, while strong support has formed around $30. Notable price patterns include a double bottom formation in August, indicating a potential reversal, but selling pressure resumed thereafter. Recent momentum has been weak, as the stock has struggled to maintain upward movement and is currently hovering just above the 52-week low. At $37.75, the current price is approximately 23% above the recent support at $30, yet down almost 35% from its 52-week high of around $60. This positioning suggests continued bearish sentiment with potential for further volatility if support levels are tested.

Recent News and Developments

Market Update

Here are the latest news and developments for Centene Corporation (CNC) stock in the past week (January 31, 2026, to February 7, 2026):

### 1

Centene Reports Q4 2025 Earnings, Beats Estimates but Posts GAAP Loss
Centene Corporation released its fourth-quarter and full-year 2025 earnings on Friday, February 6, 2026, reporting an adjusted loss of $1.19 per share, which surpassed analysts’ consensus estimate of a $1.22-$1.25 loss. The company’s revenue for the quarter reached $49.73 billion, exceeding expectations of approximately $48.41 billion. Despite beating adjusted EPS and revenue estimates, Centene reported a significant GAAP loss for the quarter, largely due to a non-cash goodwill impairment charge.

### 2

Centene Provides Optimistic FY 2026 Adjusted EPS Guidance, Signaling Stabilization
During its earnings release, Centene issued its full-year 2026 adjusted EPS guidance of greater than $3.00, exceeding the consensus analyst estimate of around $2.95. Management indicated that this positive outlook is driven by anticipated Medicaid stability, a projected recovery in the Marketplace segment’s margins, and continued progress towards achieving a break-even in Medicare Advantage by 2027, with 2026 margins close to break-even. This guidance suggests a potential stabilization of medical costs, a notable development in the managed-care industry which has faced challenges.

Market Sentiment and Analyst Recommendations

Bull Case

Centene just beat on both revenue ($49.73B vs $48.41B expected) and adjusted EPS loss ($1.19 vs $1.22-$1.25 expected), which matters when you’re in turnaround mode. Management guided 2026 adjusted EPS above $3.00, crushing the $2.95 consensus, and explicitly signaled stabilization in medical costs across Medicaid and Marketplace segments. The path to Medicare Advantage break-even by 2027 is concrete, not vague. With $19.24B in cash against $17.58B in debt, the balance sheet can fund operations while margins recover. Two analyst upgrades in quick succession (Wall Street Zen to Buy on Feb 7, Barclays to Overweight on Jan 5 with $54 target) suggest the inflection point is real. At $37.75, you’re buying 35% below the $66 peak with 21.5% revenue growth intact. The stock trades at a significant discount to its $43.88 consensus target, leaving 16% upside on analyst estimates alone.

Bear Case

Centene reported a massive GAAP loss in Q4 driven by goodwill impairment, which signals past acquisition mistakes and overpayment. The stock gapped down after earnings despite beating, closing at $38.46 Friday—the market wasn’t convinced by the guidance. The company has no positive P/E ratio because it’s not profitable on a GAAP basis, and adjusted EPS of $3+ in 2026 still means near break-even in Medicare Advantage for another full year. Medical cost inflation in managed care remains a structural headwind, and Centene’s track record shows it struggled to predict and manage these costs. The stock is down 35% from its 52-week high and trading near support at $30, suggesting institutional money is still exiting. Analyst targets range wildly from $32 to $70, reflecting genuine uncertainty about execution. GenAI integration sounds good in earnings calls but hasn’t proven margin-accretive yet.

What to Watch

Monitor Q1 2026 medical loss ratios across all three segments (Medicaid, Marketplace, Medicare Advantage) when reported in April or May—any deterioration voids the stabilization thesis. Track Marketplace margin recovery specifically; management promised improvement but this segment has been the biggest problem. Watch for execution on the 2027 Medicare Advantage break-even target; if 2026 margins aren’t “close to break-even” as promised, credibility collapses. Centene’s cash burn and debt reduction timeline matter; $19.24B cash is healthy but only if operating cash flow stays positive. Look for GenAI cost savings quantified in future earnings calls—vague statements won’t move the stock. Support at $30 is the line in the sand; a break below that triggers forced selling and repricing lower. Finally, regulatory changes to Medicaid reimbursement rates would be an immediate catalyst either way, so watch CMS announcements closely.

Analyst Consensus

HOLD

Based on 17 analyst opinions

Low Target

$32.00

Mean Target

$43.88

High Target

$70.00

Earnings and Financial Data

Sector

Healthcare

Industry

Healthcare Plans

Employees

60,500

Earnings & Dividends

Next Earnings

Feb 06, 2026

EPS (Trailing)

$-10.67

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is CNC a good stock to buy?

Centene Corporation (CNC) is currently recommended as a HOLD, with a target price of $43.88. The stock is currently trading at $37.75, which presents potential upside, but with a forward P/E of 9.37, it may be more appealing for value investors than growth-oriented ones.

What is CNC’s price target?

Analysts have set a price target of $43.88 for Centene Corporation. With the current stock price at $37.75, this reflects a potential upside of about 16%.

Does CNC pay a dividend?

Centene Corporation does not pay a dividend. Investors looking for income from dividends will need to consider other options.

What is CNC’s market cap?

Centene has a market capitalization of $18.55 billion. This positions it as a significant player in the healthcare plans sector, but investors should weigh this against its recent stock performance.

What is CNC’s 52-week stock range?

CNC’s stock has traded between $25.08 and $66.03 over the past 52 weeks. This wide range indicates high volatility, making it crucial for investors to assess their risk tolerance before entering.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.